Sign inJoin waitlistJoin the waitlist

Matthew Goetz

Enterprise Deputy Director, Translational Research, Mayo Clinic Comprehensive Cancer Center · Mayo Clinic College of Medicine and Science

Credentials: · · ·

History

Department of Oncology · Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present

Hematology and Medical Oncology
Mayo Clinic College of Medicine and Science
1999–2002
Mayo Clinic College of Medicine and Science
Internal Medicine
University of Michigan
1996–1999
Univ of North Dakota Sch of Med and Hlth Sci
1992–1996

Research

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
New England Journal of Medicine · 2018 · 1,827 citations
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Journal of Clinical Oncology · 2017 · First of 18 authors · 1,415 citations
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2022 · 759 citations

James Ingle
101 papers
Judy Boughey
73 papers · 6 as a resident
Richard Weinshilboum
53 papers
JC
Jodi Carter
25 papers
Roberto Leon-Ferre
24 papers
Donald Northfelt
23 papers
Hope Rugo
23 papers
Tufia Haddad
23 papers
Harold Burstein
19 papers
Ingrid Mayer
18 papers
ME
Matthew Ellis
18 papers
EP
Edith Perez
16 papers

Grants

Mayo Clinic Breast Cancer SPORE
National Cancer Institute · P50
Contact PI · $31.8M · Mayo Clinic Rochester
2005–2027
Mayo Clinic Comprehensive Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $476.7K · Mayo Clinic Rochester
1997–2025
Tamoxifen Biotransformation Pathway Pharmacogenomics
National Cancer Institute · R01
Contact PI · $2.3M · Mayo Clinic Rochester
2008–2014

Clinical trials

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Principal investigator · Terminated · Phase 2
Mayo Clinic
2020–2024
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
Principal investigator · Active not recruiting · Phase 2
Mayo Clinic
2019–2026
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2011–2026
AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
Principal investigator · Completed · Phase 1
National Cancer Institute (NCI)
2006